PLE01:  Keynote Lecture: Advances in monitoring immunotherapies

• Petra Reinke - MonitoringTreg therapy in SOT

PLE-02: ESCCA-ICCS joint session: Standardization in Clinical Flow Cytometry: Design, Validation, and Analysis

• Virginia Litwin - Using CLSI H62 to Bring Quality to the Clinical Flow Cytometry Laboratory
• Ahmad Al-Attar - Education leads to standardization
• Wolfgang Kern - Standardization in MRD AML

PLE03: ESCCA-EHA joint session: Clinical results in Measurable Residual Disease (MRD)-driven trials

• Andy Rawstron - The role of MRD in current treatment strategies for CLL
• Noemi Puig - Role of minimal residual disease in multiple myeloma: different techniques for a crucial biomarker

PLE05: ESCCA-ESID joint session

• Mirjam van der Burg: B-cell development in a new context: new insights based on inborn errors of immunity

PLE06: Immunology: Interactive Case Presentation

• Mirjam van der Burg: Interactive cases on inborn errors of immunity

PLE08: Keynote Lecture

• Bruno Paiva - Dissecting MM: from flow-cytometry to single-cell sequencing 

PLE09: Hemato-Oncology: Interactive Case Presentation

• Arianna Gatti - Breast cancer with the presence of a large number of atypical cells in peripheral blood mimicking acute myeloid leukemia: a case report 

Advances in hemato-oncological diseases

PAR01: The WHO2022/ICC new classifications: what has changed in the diagnostic approach to hematological malignancies?

• Kees Meijer & Maximiliano Ramia De Cap

PAR04: Headline 2023 news in cellular therapy of hematological malignancies

• Monica Guzman - Targeting CD123 from immunotherapy to CART: BPDCN and beyond
• Reuben Benjamin - CAR T cell treatment for CD19 positive malignancies

PAR07: Machine learning approaches in flow-cytometry analysis

• Sarah Bonte - Translating computational flow cytometry to the clinic
• Margarita Maurer-Granofszky & Michael Reiter - Machine learning for automated FLOW-MRD assessment​

PAR10: Dissecting complexity of Hematological malignancies

• Lydia Campos - Phenotypic myeloid alterations in Monoclonal Gammopathy of undetermined significance and in de novo myeloma patients
• Catia Simoes - Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia 

PAR13: New developments PNH treatment and diagnostics

• Frank Preijers - Developments in diagnostics to monitor PNH clones and complement activation
• Bruno Fattizzo - Modern treatment approaches to PNH treatment

Validation approaches in clinical FC

PAR02: Validation and standardisation of functional assays

• José Enrique O'Connor - Functional assays of platelet in whole blood
• Hanna IJspeert - Phospho-assays for research and diagnostics of IEI 

PAR05: How IVDR will change my lab

• Pieter Bogaert - IVDR and flow cytometry: impact on routine diagnostics and clinical trials
• Iuri Marinov - Assessment of Immature PNH RBCs (iRBCs) by Flow Cytometry: Assay Validation following the EU 2017/746-IVDR for In-house Devices

PAR08: A practical approach to IVDR

• Sylvie Freeman - Harmonization efforts in AML MRD 
• Adrian Schwarzer - Development of full spectrum flow cytometry assays for the detection of measurable residual disease in acute myeloid leukemia

PAR11: Validation/harmonization of ALL-MRD

• Vincent van der Velden - Standardized flowcytometric MRD analysis in BCP-ALL patients
• Lukasz Sędek - Challenges in MRD analysis in T-ALL by flow cytometry

PAR14: Validated approach to T-cell/B-cell lympho-proliferative disorders diagnosis and monitoring

• Julia Almeida - New flow-cytometry approaches for diagnosis (of clonality), classification and monitoring of T-cell CLPD
• Massimo Geuna - B-LPD, diagnosis beyond typical immunophenotypic fingerprint entities

Cutting-edge immunology

 PAR03: Towards the definition of the immunological ‘normal’ across different age groups

• Ester Mejstríková - Defining the normal: new approaches for harmonized subset definitions and gating procedures
• Jaromir Mikes - Minimize technical variation to see a more biological signal - optimized blood sampling methods in Systems Immunology

PAR06:Cytometry in neurological & psychiatric diseases

• Tilman Schneider-Hohendorf - Broader Epstein–Barr virus–specific T cell receptor repertoire in patients with multiple sclerosis
• Marvin van Luijn - Defining T cells poised to infiltrate the brain and trigger multiple sclerosis

PAR09: Cytometry in the diagnosis of inborn errors of innate immunity

• Lisette van de Corput - Neutrophil oxidative burst capacity and NK cell function assays in cellular diagnostics
• Evelien Sprenkeler - Functional studies on inborn errors of innate immunity

PAR12: Autoimmunity, chronic inflammatory disease, and immune tolerance

• Carina Saggau - Ag-specific T-cells in autoimmunity 
• Asbjørn Christophersen -Direct isolation of disease-driving T cells in celiac disease without using HLA multimers

PAR15: Clinical cytometry in transplantation 

• Britt-Marie Ekman-Joelsson - Immunological differences between heart- and kidney-transplanted children
• Wouter Woud - Direct detection of single extracellular vesicles in kidney transplantation